Why the study?
Does the juglone derivative J2 inhibit breast cancer cell proliferation and disrupt doxorubicin-driven pro-migratory stromal–tumor signaling?
Population
Breast cancer cell lines (ZR75–1, MCF7, and MDA-MB-231) and RMF621 fibroblasts
Comparison
Juglone derivative J2 (Cpd. J2) vs Control / Doxorubicin alone
Design
Preclinical
Key result
The juglone derivative Cpd. J2 modulated mitochondrial redox balance via NQO1, inhibiting breast cancer cell proliferation and disrupting doxorubicin-driven pro-migratory stromal-tumor signaling.
Authors
Loading...
May attenuate Doxo-driven invasion in breast cancer models; hypothesis-generating and requires in vivo validation before any clinical consideration.
Does the juglone derivative J2 inhibit breast cancer cell proliferation and disrupt doxorubicin-driven pro-migratory stromal–tumor signaling?
The juglone derivative J2 modulates mitochondrial redox balance and disrupts doxorubicin-induced pro-migratory signaling between stromal and breast cancer cells in vitro.
Rodríguez-Lucart et al. (2026) studied Breast cancer. Juglone derivative J2 (Cpd. J2) was evaluated on Cell proliferation, mitochondrial bioenergetics, and Doxo-induced pro-migratory signaling. The juglone derivative Cpd. J2 modulated mitochondrial redox balance via NQO1, inhibiting breast cancer cell proliferation and disrupting doxorubicin-driven pro-migratory stromal-tumor signaling.